MRVI

Maravai LifeSciences Holdings, Inc. [MRVI] Stock Forecast

Q: What is Maravai LifeSciences Holdings, Inc. stock symbol ?

Maravai LifeSciences Holdings, Inc. is a US stock, located in San diego of Ca and trading under the symbol MRVI

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

MRVI Stock Summary

Earnings have grown 10.48% per last year.

The Moving Average Convergence Divergence (MACD) for MRVI recently turned positive (within last 10 days).

Earnings are expected to fall -53.83% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Profit margins (0.17%) are lower than the previous year (0.56%)

MRVI has less than 1 year of cash runway

Debt-to-Equity ratio of 1.07 is considered moderate, deeper research suggested.

Top 10 Correlated ETFs

MRVI

Top 10 Correlated Stocks

MRVI

In the News

08:15 30 Nov 2023 MRVI

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.

03:54 30 Nov 2023 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Deb Hart - Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Executive Vice President and Chief Commercial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tom Peterson - Baird Matt Larew - William Blair Michael Ryskin - Bank of America Conor McNamara - RBC Capital Markets Dan Arias - Stifel Justin Bowers - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.

08:15 30 Nov 2023 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023

SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

04:36 30 Nov 2023 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2023 Earnings Call Transcript August 7, 2023 5:00 PM ET Company Participants Debra Hart - Head of IR Carl Hull - Executive Chairman of the Board Trey Martin - CEO Kevin Herde - CFO Becky Buzzeo - CCO Drew Burch - EVP, and GM Nucleic Acid Production Conference Call Participants Matt Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Dan Leonard - Credit Suisse Catherine Schulte - Baird Justin Bowers - Deutsche Bank Tejas Savant - Morgan Stanley Madeline Mollman - William Blair John Sourbeer - UBS Operator Thank you for standing by. I would like to welcome everyone to the Quarter Two 2023 Maravai LifeSciences' Earnings Conference Call.

04:05 30 Nov 2023 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Monday, August 7, 2023

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

07:52 30 Nov 2023 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chairman of the Board and Interim CEO Kevin Herde - Chief Financial Officer Becky Buzzeo - Chief Commercial Officer Trey Martin - President Biologics Safety Testing Drew Burch - EVP, Nucleic Acid Production Conference Call Participants Conor McNamara - RBC Capital Markets Catherine Schulte - Robert W. Baird Matthew Sykes - Goldman Sachs Daniel Leonard - Credit Suisse Daniel Arias - Stifel John Sourbeer - UBS Tejas Savant - Morgan Stanley Operator Good afternoon.

07:02 30 Nov 2023 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.54 per share a year ago.

04:15 30 Nov 2023 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 8, 2023

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2023 financial and operating results after the market closes on Monday, May 8, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

08:45 30 Nov 2023 MRVI

2 Top Biotech Stocks to Buy In March and Hold Forever

Long-term investments in biotech tend to be hard to come by. Moderna's gargantuan pipeline means that it has a very long growth runway ahead.

08:00 30 Nov 2023 MRVI

Maravai LifeSciences Announces March 2023 Investor Conference Schedule

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March.

MRVI Financial details

Company Rating

Strong Buy

Market Cap

1.34B

Income

73.08M

Revenue

419.52M

Book val./share

3.94

Cash/share

4.39

Dividend

Dividend %

Employees

670

Optionable

Shortable

Yes

Earnings

20 Feb 2024

P/E

9.24

Forward P/E

64.69

PEG

-1.07

P/S

3.07

P/B

1.3

P/C

1.18

P/FCF

4.8

Quick Ratio

16.7

Current Ratio

8.96

Debt / Equity

1.07

LT Debt / Equity

0.62

EPS (TTM)

0.55

EPS next Y

0.08

EPS next Q

0.02

EPS this Y

-8.8%

EPS next Y

-85.49%

EPS next 5Y

-49.53%

EPS last 5Y

NAN%

Revenue last 5Y

48.12%

Revenue Q/Q

-2.97%

EPS Q/Q

-1.21%

SMA20

-28.57%

SMA50

-50%

SMA100

-58.33%

Inst Own

66.8%

Inst Trans

0.71%

ROA

ROE

14%

ROC

0.04%

Gross Margin

60%

Oper. Margin

19%

Profit Margin

17%

Payout

Shs Outstand

251.28M

Shs Float

103.02M

Target Price

23.5

52W Range

4.52-16.9

52W High

-67.66%

52W Low

+29.38%

RSI

Rel Volume

0.7

Avg Volume

2.66M

Volume

1.87M

Perf Week

4.97%

Perf Month

-28.03%

Perf Quarter

-60.28%

Perf Half Y

-60.22%

Beta

-0.112

Volatility

0.11%, 0.85%

Prev Close

1.07%

Price

5.175

Change

1.67%

MRVI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.39	1.61	27.45	6.96	6.71
Net income per share	-0.2	-0.06	8.6	4.09	3.73
Operating cash flow per share	0	0.27	14.7	3.21	4.07
Free cash flow per share	-0.04	0.08	12.25	3.08	3.94
Cash per share	0.25	0.28	22.82	4.8	4.81
Book value per share	1.62	1.59	8.55	2.75	4.14
Tangible book value per share	-3.31	-3.12	-23.88	2.4	3.08
Share holders equity per share	1.62	1.59	8.55	2.75	4.14
Interest debt per share	4.13	4.72	60.04	4.92	4.6
Market cap	2.66B	2.66B	290.35M	4.81B	1.88B
Enterprise value	2.97B	3.02B	644.94M	4.79B	1.84B
P/E ratio	-149.77	-510.6	3.26	10.25	3.84
Price to sales ratio	21.45	18.55	1.02	6.02	2.13
POCF ratio	-14.28K	110.12	1.91	13.05	3.51
PFCF ratio	-699.4	381.17	2.29	13.6	3.63
P/B Ratio	18.39	18.78	3.28	15.24	3.45
PTB ratio	18.39	18.78	3.28	15.24	3.45
EV to sales	24.01	21.11	2.27	6	2.08
Enterprise value over EBITDA	74.7	62.28	6.9	8.82	3.23
EV to operating cash flow	-15.99K	125.28	4.24	13	3.42
EV to free cash flow	-783.16	433.63	5.09	13.55	3.54
Earnings yield	-0.01	0	0.31	0.1	0.26
Free cash flow yield	0	0	0.44	0.07	0.28
Debt to equity	2.35	2.76	6.67	1.69	1.07
Debt to assets	0.63	0.68	0.46	0.28	0.26
Net debt to EBITDA	7.99	7.53	3.8	-0.03	-0.08
Current ratio	1.5	2.05	2.54	7.89	7.7
Interest coverage	0.6	0.8	2.2	18.33	28.13
Income quality	0.01	-4.64	1.93	0.79	1.09
Dividend Yield	0.02	0	2.1	0	0
Payout ratio	-2.94	0	6.85	0	0
Sales general and administrative to revenue	0.33	0	0	0	0
Research and developement to revenue	0.04	0.03	0.03	0.02	0.02
Intangibles to total assets	0.82	0.73	0.32	0.14	0.22
Capex to operating cash flow	19.41	-0.71	-0.17	-0.04	-0.03
Capex to revenue	-0.03	-0.12	-0.09	-0.02	-0.02
Capex to depreciation	-0.16	-0.71	-0.98	-0.6	-0.45
Stock based compensation to revenue	0.02	0.01	0.09	0.01	0.02
Graham number	2.7	1.45	40.67	15.9	18.65
ROIC	0.03	0.04	0.09	0.57	0.43
Return on tangible assets	-0.18	-0.03	0.1	0.28	0.28
Graham Net	-3.94	-4.36	-79.69	-6.17	-4.66
Working capital	17.88M	30.99M	200.82M	646.26M	737.76M
Tangible asset value	-294.39M	-277.5M	-247.19M	275.02M	404.91M
Net current asset value	-337.86M	-372.62M	-784.35M	-632.88M	-529.17M
Invested capital	2.35	2.76	6.67	1.69	1.07
Average receivables	0	17.01M	34.52M	84.27M	132.16M
Average payables	0	5.54M	7.82M	8.16M	7.07M
Average inventory	0	14.26M	23.75M	42.43M	47.35M
Days sales outstanding	47.13	45.98	65.55	53.67	60.69
Days payables outstanding	21.65	40.83	37.44	21.17	12.94
Days of inventory on hand	85.94	77.54	152.61	133.88	93.22
Receivables turnover	7.74	7.94	5.57	6.8	6.01
Payables turnover	16.86	8.94	9.75	17.24	28.2
Inventory turnover	4.25	4.71	2.39	2.73	3.92
ROE	-0.12	-0.04	1.01	1.49	0.9
Capex per share	-0.04	-0.19	-2.45	-0.13	-0.13

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.45	1.56	0.6	0.52	0.51
Net income per share	0.76	0.66	-0.01	-0.05	-0.05
Operating cash flow per share	0.84	0.75	0.65	0.15	0
Free cash flow per share	0.79	0.71	0.59	-0.04	0
Cash per share	4.69	4.8	4.77	4.4	4.39
Book value per share	3.83	4.14	3.96	3.95	3.94
Tangible book value per share	2.55	3.08	2.52	2.55	2.56
Share holders equity per share	3.83	4.14	3.96	3.95	3.94
Interest debt per share	4.08	4.52	4.77	4.73	4.31
Market cap	3.36B	1.88B	1.85B	1.64B	1.32B
Enterprise value	3.27B	1.84B	1.83B	1.68B	1.3B
P/E ratio	8.42	5.39	-342.3	-62.65	-51.04
Price to sales ratio	17.56	9.2	23.36	23.78	19.73
POCF ratio	30.51	18.96	21.69	85.39	0
PFCF ratio	32.42	20.23	23.91	-279.47	0
P/B Ratio	6.67	3.45	3.54	3.15	2.54
PTB ratio	6.67	3.45	3.54	3.15	2.54
EV to sales	17.12	8.97	23.2	24.32	19.4
Enterprise value over EBITDA	28.01	16.33	209.66	-191.36	-234.43
EV to operating cash flow	29.76	18.49	21.55	87.33	0
EV to free cash flow	31.61	19.72	23.75	-285.79	0
Earnings yield	0.03	0.05	0	0	0
Free cash flow yield	0.03	0.05	0.04	0	0
Debt to equity	1.06	1.07	1.18	1.19	1.07
Debt to assets	0.24	0.26	0.27	0.27	0.25
Net debt to EBITDA	-0.71	-0.42	-1.37	-4.23	3.97
Current ratio	7.22	7.7	6.13	9.33	8.96
Interest coverage	37.28	10.73	-0.18	-1.65	-1.32
Income quality	1.1	1.14	-63.11	-1.61	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.03	0.02	0.05	0.06	0.07
Intangibles to total assets	0.23	0.22	0.25	0.25	0.24
Capex to operating cash flow	-0.06	-0.06	-0.09	-1.31	0
Capex to revenue	-0.03	-0.03	-0.1	-0.36	0
Capex to depreciation	-0.65	-0.62	-0.72	-2.12	0
Stock based compensation to revenue	0.02	0.03	0.08	0.13	0
Graham number	8.08	7.87	0.95	2.1	2.08
ROIC	0.1	0.08	0	-0.01	-0.01
Return on tangible assets	0.06	0.05	0	0	0
Graham Net	-5.01	-4.66	-5.44	-5.51	-1.71
Working capital	719.87M	737.76M	640.62M	624.39M	622.61M
Tangible asset value	335.24M	404.91M	332.49M	336.45M	338.4M
Net current asset value	-571.7M	-529.17M	-649.24M	-667.49M	-674.41M
Invested capital	1.06	1.07	1.18	1.19	1.07
Average receivables	130.58M	139.52M	101.85M	53.05M	388.41M
Average payables	16.36M	7.73M	5.39M	5.72M	8.04M
Average inventory	61.27M	52.79M	48.99M	51.11M	48.27M
Days sales outstanding	62.22	64.55	64.79	64.28	979.35
Days payables outstanding	22.3	10.13	12.79	13.85	23.12
Days of inventory on hand	147.16	72.93	146.51	98.59	120.56
Receivables turnover	1.45	1.39	1.39	1.4	0.09
Payables turnover	4.04	8.89	7.04	6.5	3.89
Inventory turnover	0.61	1.23	0.61	0.91	0.75
ROE	0.2	0.16	0	-0.01	-0.01
Capex per share	-0.05	-0.05	-0.06	-0.19	0

MRVI Frequently Asked Questions

What is Maravai LifeSciences Holdings, Inc. stock symbol ?

Maravai LifeSciences Holdings, Inc. is a US stock , located in San diego of Ca and trading under the symbol MRVI

Is Maravai LifeSciences Holdings, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $23.5. The lowest prediction is $22 and the highest is $25

What is MRVI stock prediction ?

What is Maravai LifeSciences Holdings, Inc. stock quote today ?

Maravai LifeSciences Holdings, Inc. stock price is $5.175 today.

Is Maravai LifeSciences Holdings, Inc. stock public?

Yes, Maravai LifeSciences Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.66M
Market Capitalization 1.34B
Employee 670
CEO Mr. William E. Martin III
Headquarters San Diego,CA,US
IPO Date 2020-11-20
Website https://www.maravai.com

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.